Benjamin F. Edwards & Company, Inc. Esperion Therapeutics, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 325 shares of ESPR stock, worth $747. This represents 0.0% of its overall portfolio holdings.
Number of Shares
325
Previous 325
-0.0%
Holding current value
$747
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ESPR
# of Institutions
206Shares Held
128MCall Options Held
1.67MPut Options Held
930K-
Wasatch Advisors Inc Salt Lake City, UT23.3MShares$53.7 Million0.19% of portfolio
-
Black Rock Inc. New York, NY14MShares$32.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$30 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$22.9 Million0.28% of portfolio
-
Two Seas Capital LP Rye, NY6.58MShares$15.1 Million3.65% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $153M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...